Yes, the answer could be as simple as that. i a
Post# of 144708
i am clueless as to the FDA protocols.
But it seems to me that its not too complicated to do a phase 1 trial with twenty patients and very close monitoring of RO with intravenous dosing.
But becasue of the Patterson/Pourhassan split, Cytodyn couldn't do that.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)